Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Dec 2024
Little is being done to curb the risk
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
2.
Disparities in use of MRI to detect prostate cancer: Race and location may influence testing
3.
Alone for 500 Days, but Never Lonely: The Introvert's Dream.
4.
Millions of men could benefit from faster scan to diagnose prostate cancer
5.
Team finds broken 'brake' on cancer mutation machine.
1.
Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics
2.
Unravelling the Mysteries of Monoclonal Gammopathy
3.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
4.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
5.
The Statistical Frontier of Hematology Oncology: Diagnostics, Therapies, and Future Horizons in Hematology Oncology 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
Oropharyngeal Cancer in Relation to HPV Status
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge